Skip to content

US · CDXS · BIOTECHNOLOGY

Codexis, Inc. (CDXS) intrinsic value and stock valuation

$1.01as of 2026-11-21 · Mkt cap 131.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Codexis, Inc. DCF and intrinsic value

InvestorsCraft values CDXS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CDXS’s statements →

Codexis, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94063 codexis.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$70.4M+0.4% 5y CAGRd
20112025
Net income
-$-43.97M
20112025
Free cash flow
-$-23.85M
20112025
Total equity
$50.5M-21.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$70.4M$59.3M$70.1M$138.6M$104.8M
Operating income-$-38.33M-$-58.52M-$-68.07M-$-34.88M-$-22.7M
Net income-$-43.97M-$-65.28M-$-76.24M-$-33.59M-$-21.28M
EPSd-$-504.59K-$-889.25K-$-1.12M-$-514.08K-$-329.56K
Operating cash flow-$-19.38M-$-49.41M-$-52.64M$11.3M-$-14.27M
Capital expenditure-$-4.47M-$-4.3M-$-4.42M-$-8.31M-$-13.83M
Free cash flow-$-23.85M-$-53.72M-$-57.06M$2.98M-$-28.09M
Total assets$147.8M$149M$136.6M$250.4M$246.4M
Total debt$73.2M$59.9M$16M$43.6M$47.7M
Net debt$22.4M$40.6M-$-49.09M-$-70.35M-$-69.14M
Total equity$50.5M$66.9M$86.6M$144.8M$164.4M
Cash and short-term investments$78.2M$73.5M$65.1M$114M$116.8M
Income statement
20252024202320222021
Revenue$70.4M$59.3M$70.1M$138.6M$104.8M
Cost of revenue$9.34M$16.3M$12.8M$38M$22.2M
Gross profit$61.1M$43.1M$57.3M$100.6M$82.6M
Research and development expenses$52.3M$46.3M$58.9M$80.1M$55.9M
Selling, general and administrative expenses$47.1M$55.2M$53.3M$52.2M$49.3M
Other expenses$0.00$170K$13.3M$3.17M$0.00
Operating expenses$99.4M$101.6M$125.4M$135.4M$105.2M
Cost and expenses$108.7M$117.9M$138.2M$173.5M$127.5M
Interest income$2.62M$3.67M$4.17M$1.44M$460K
Interest expense$4.81M$0.00$0.00$0.00$0.00
Depreciation and amortization$5.25M$4.95M$5.52M$5.4M$5.95M
Ebitda-$-33.87M-$-53.41M-$-49.28M-$-26.31M-$-15.14M
Operating income-$-38.33M-$-58.52M-$-68.07M-$-34.88M-$-22.7M
Total other income/expenses, net-$-5.59M-$-6.72M-$-8.1M$1.56M$1.61M
Income before tax-$-43.93M-$-65.24M-$-76.17M-$-33.32M-$-21.09M
Income tax expense$50K$30K$70K$280K$190K
Net income-$-43.97M-$-65.28M-$-76.24M-$-33.59M-$-21.28M
Weighted average shares outstanding$87.1M$73.4M$68.1M$65.3M$64.6M
Weighted average diluted shares outstanding$87.1M$73.4M$68.1M$65.3M$64.6M
Balance sheet
20252024202320222021
Cash and short-term investments$78.2M$73.5M$65.1M$114M$116.8M
Net receivables$10.7M$18.9M$19.9M$40.9M$37.7M
Inventory$1.82M$1.8M$2.69M$2.03M$1.16M
Total current assets$96.8M$98.8M$93.5M$162.9M$161.9M
Property, plant and equipment, net$43.5M$42.9M$28.6M$61.9M$65.5M
Goodwill and intangible assets$2.46M$2.46M$2.46M$3.24M$3.24M
Long-term investments$2.5M$2.8M$9.7M$20.5M$14M
Total non-current assets$51M$50.2M$43.1M$87.5M$84.5M
Total assets$147.8M$149M$136.6M$250.4M$246.4M
Accounts payable$1.55M$2.84M$5.95M$3.25M$3M
Short-term debt$2.94M$2.83M$3.78M$5.36M$4.09M
Deferred revenue$7.01M$350K$10.1M$13.7M$2.59M
Total current liabilities$25.3M$23.7M$35.8M$49.1M$33.4M
Long-term debt$70.3M$57.1M$12.2M$38.3M$43.6M
Deferred revenue, non-current$360K$100K$640K$16.9M$3.75M
Total non-current liabilities$72M$58.4M$14.1M$56.5M$48.6M
Capital lease obligations$33.1M$31M$16M$43.6M$47.7M
Total liabilities$97.3M$82.1M$50M$105.6M$82M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-606.78M-$-562.81M-$-497.53M-$-421.29M-$-387.7M
Accumulated other comprehensive income (loss)$10K$50K$0.00$0.00$0.00
Total equity$50.5M$66.9M$86.6M$144.8M$164.4M
Total investments$29.9M$57M$9.7M$20.5M$14M
Total debt$73.2M$59.9M$16M$43.6M$47.7M
Net debt$22.4M$40.6M-$-49.09M-$-70.35M-$-69.14M
Cash flow statement
20252024202320222021
Net income-$-43.97M-$-65.28M-$-76.24M-$-33.59M-$-21.28M
Depreciation and amortization$5.25M$4.95M$9.92M$10.3M$5.95M
Stock-based compensation$9.62M$13.1M$9.97M$14.5M$11.6M
Change in working capital$6.42M-$-12.02M-$-18.22M$21.6M-$-7.62M
Accounts receivable$8.51M$1.25M$20.3M-$-3.23M-$-15.57M
Inventory-$-20K$890K-$-660K-$-870K-$-200K
Accounts payable-$-1.29M-$-2.57M$2.29M$210K$270K
Net cash provided by operating activities-$-19.38M-$-49.41M-$-52.64M$11.3M-$-14.27M
Investments in property, plant and equipment-$-4.47M-$-4.3M-$-4.42M-$-8.31M-$-13.83M
Acquisitions, net$10K$90K$750K$30K$40K
Net cash used for investing activities$23.5M-$-56.98M-$-4.86M-$-13.58M-$-21.42M
Common stock issued$18M$31.3M$8.65M$910K$4.97M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.9M$60.5M$8.17M-$-570K$3.77M
Net change in cash$32.1M-$-45.87M-$-49.33M-$-2.87M-$-31.92M
Cash at end of period$52.9M$20.8M$66.7M$116M$118.9M
Operating cash flow-$-19.38M-$-49.41M-$-52.64M$11.3M-$-14.27M
Capital expenditure-$-4.47M-$-4.3M-$-4.42M-$-8.31M-$-13.83M
Free cash flow-$-23.85M-$-53.72M-$-57.06M$2.98M-$-28.09M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Codexis, Inc.

        Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

        CEO
        Alison Moore
        Employees
        146
        Beta
        2.50

        Explore

        Frequently asked questions

        What is the intrinsic value of Codexis, Inc. (CDXS)?

        InvestorsCraft does not currently publish an intrinsic value for CDXS. How the IC value is calculated.

        Is CDXS undervalued?

        InvestorsCraft does not publish an undervaluation signal for CDXS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.